Renibus Therapeutics Announces Final Close Of Upsized Series B Financing, Bringing Total Round To $72 Million
Round Type
Series B
SouthlakeBiotechnologyHealthcareHealth CareMedicalTherapeuticsBiopharmaInvestors
Description
Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced the close of an extension to its Series B financing round, bringing the total amount raised to $72 million. Renibus' investors are comprised of existing and new investors, including leaders in the cardiac surgery community.
Quick answer
Renibus Therapeutics raised an undisclosed amount in a Series B round, dated September 12, 2023. Investors: Renibus. Renibus Therapeutics is based in Southlake, Texas, United States.
- How much did Renibus Therapeutics raise?
- Renibus Therapeutics raised an undisclosed amount in a Series B round on September 12, 2023.
- Who invested in Renibus Therapeutics?
- Renibus is named as investors in this round.
- What does Renibus Therapeutics do?
- Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases.
- Where is Renibus Therapeutics based and how big is it?
- Renibus Therapeutics is based in Southlake, Texas, United States. Fundz records about 332 employees.
- Who are the decision-makers at Renibus Therapeutics?
- Fundz holds 1 contact at Renibus Therapeutics, including the Co-Founder, President and COO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Medical around the same time
Companies in the same sectors as Renibus Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
- Aligos Therapeutics raised $92M on October 25, 2023.
- Azora Therapeutics, Inc. (DE) raised $4M (Seed) on October 19, 2023.
- Actym Therapeutics raised $60M (Series A) on October 18, 2023.
- Purple Biotech raised $5.4M on October 17, 2023.
- Greenbrook TMS raised $1.5M (Seed) on October 13, 2023.
Who to call at Renibus Therapeutics, and when
A new round usually means Renibus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Renibus Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Renibus Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Renibus Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Renibus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRenibus Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.